Why the GSK share price should smash the FTSE 100 this year

Roland Head takes a look at FTSE 100 (INDEXFTSE:UKX) climber GlaxoSmithKline plc (LON:GSK) and highlights another turnaround opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares of pharma giant GlaxoSmithKline (LSE: GSK) have risen by 15% so far this year, outpacing a flat performance from the FTSE 100.

I first suggest this stock as a turnaround buy back in January and then again in March when news broke of the group’s decision to buy out Novartis from the pair’s consumer healthcare joint venture for $13bn.

At that time the stock was trading on around 12 times 2018 forecast earnings and offering a 6% yield. The group’s rising share price has upped this price tag. Glaxo shares now trade on 14 times 2018 forecast earnings, with a 5.3% yield.

For comparison, the FTSE 100 currently trades on a P/E of 13.5 with a dividend yield of 3.8%. So Glaxo looks still reasonably priced compared to the index. And the group may also have some tricks up its sleeve.

Staying together could be profitable

A number of prominent investors including Neil Woodford have called for the group to break itself up into two or three smaller and more focused businesses. I have some sympathy with this view, but it seems that chief executive Emma Walmsley isn’t keen.

Ms Walmsley appears determined to keep the group together and improve its performance by bulking up in key areas of strength. The acquisition of the remaining share of the Consumer Healthcare joint venture is an example of this.

This decision isn’t without risk. Much of the $13bn recently paid to Novartis for its share of the consumer healthcare business was funded with debt. But the operating margin from selling products such as Panadol and Sensodyne is expected to rise from 17.7% in 2017 to “mid-20s percentages” by 2022.

I estimate that achieving this alone could add about £550m to Glaxo’s 2017 operating profit of £4.1bn, even before any sales growth is considered.

I still see value

At Glaxo’s current valuation, I believe the shares still offer decent value for long-term income investors. Although this group has underperformed the market over the last five years, profits seem to have stabilised and free cash flow is improving. This should support both the dividend and some level of debt reduction.

For income investors, I believe Glaxo’s 5.3% yield represents a decent buy.

This 6% yielder could motor ahead

Public transport operators are not exactly the flavour of the month at the moment. Many rail commuters will know why. But my pick from this sector, FTSE 250 firm Go-Ahead Group (LSE: GOG), looks like a potential value buy to me.

As with Glaxo, Go-Ahead’s share price has motored ahead this year. The stock is now worth about 10% more than at the start of January.

What’s changed?

The group’s troubled Southern Rail franchise has gathered a lot of headlines. But the reality is that the financial results of the rail division were ahead of expectations during the six months to 31 December. The group’s bus operations are also performing well and a number of new overseas contracts are in the pipeline.

Revenue rose by 6.6% to £1,829.4m during the half-year, while operating profit climbed 19% to £86.9m. The group’s third-quarter trading statement shows that this performance has continued, with profit guidance left unchanged for buses and upgraded for rail.

A cash machine

The company seems to be leaving last year’s problems behind. And its financial performance is improving. Cash generation has always been a core attraction here and this is starting to recover, after a difficult period in 2016/17.

I estimate that Go-Ahead’s forecast dividend of 102p per share should be covered by free cash flow this year. With a 2017/18 price/earnings ratio of 8.9 and a forecast dividend yield of 6.1%, this stock is on my buy list at the moment.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »